Similar articles

• Selegiline for Parkinson's disease.

  Calesnick B. Calesnick B. Am Fam Physician. 1990 Feb;41(2):589-91. Am Fam Physician. 1990. PMID: 2105624 Clinical Trial.
• Deprenyl in the treatment of Parkinson's disease. A specific type B monoamine oxidase inhibitor.

  Lieberman AN, Gopinathan G, Neophytides A, Hiesiger E, Nelson J, Walker R, Goodgold A. Lieberman AN, et al. N Y State J Med. 1984 Jan;84(1):13-6. N Y State J Med. 1984. PMID: 6422358 No abstract available.
• Deprenyl and levodopa and Parkinson's disease progression.

  Fowler JS, Fazzini E, Volkow ND. Fowler JS, et al. Ann Neurol. 1996 Aug;40(2):267-8. doi: 10.1002/ana.410400228. Ann Neurol. 1996. PMID: 8773616 No abstract available.
• [Optimization of the treatment of Parkinson's disease using dopamine agonists].

  Rinne UK. Rinne UK. Arch Neurobiol (Madr). 1991 Nov-Dec;54(6):282-7. Arch Neurobiol (Madr). 1991. PMID: 1687430 Review. Spanish. No abstract available.
• Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.

  Henchcliffe C, Schumacher HC, Burgut FT. Henchcliffe C, et al. Expert Rev Neurother. 2005 Nov;5(6):811-21. doi: 10.1586/14737175.5.6.811. Expert Rev Neurother. 2005. PMID: 16274338 Review.